When the CIS/MS group was split into patients with CIS and patients with MS, a significant increase in CD40 expression was observed only in plasmablasts of MS patients compared to CIS patients (p=0.04), whereas no differences were found for the other B cell subsets (Figure 4) or for CD71 expression (Supplementary Figure S5). The gene discussed is TFRC; the disease is in situ carcinoma.